Cromos Pharma

AI is no longer viewed simply as a tool for operational efficiency in clinical trials.

The FDA is increasingly positioning AI as part of the clinical development infrastructure itself, with growing focus on governance, oversight, transparency, and regulatory trust.
In this article, we explore what the FDA’s recent initiatives could mean for the future of clinical research and why the industry may be entering a new phase of AI adoption.

Read more: https://cromospharma.com/fda-ai-and-the-future-of-clinical-trials/

On World Clinical Trials Day, the conversation is no longer only about innovation.

As clinical trials become more complex across operations, technology, patient recruitment, and site management, the industry is facing a new challenge: not just developing therapies, but delivering trials efficiently at scale.

In our latest article, we explore the key trends shaping clinical research in 2026. Read more: https://cromospharma.com/world-clinical-trials-day-clinical-research-is-not-where-it-used-to-be/?preview_id=11753&preview_nonce=c21d76b9e3&_thumbnail_id=11754&preview=true